Fiche publication
Date publication
novembre 2011
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VERGES Bruno
Tous les auteurs :
Verges B, Duvillard L, Brindisi MC, Gautier E, Krempf M, Costet P, Cariou B
Lien Pubmed
Résumé
Objective: Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a post-transcriptional inhibitor of LDL-receptor. In non-diabetic men, plasma PCSK9 levels were found to be inversely correlated with low-density lipoprotein (LDL) apolipoprotein B100 (apoB) fractional catabolic rate (FCR). Here, we aimed to determine the effect of type 2 diabetes on the association between plasma PCSK9 and FCR of LDL. Methods: A kinetic study of LDL-apoB100, using stable isotopes, was performed in 38 individuals (20 men, 18 women) including 23 non-diabetic normolipidemic subjects and 15 patients with type 2 diabetes. Results: In the non-diabetic group, plasma PCSK9 was positively correlated with LDL-C (r = 0.64, p = 0.001), apoB (r = 0.67, p < 0.001), and inversely correlated with LDL-apoB FCR (r = -0.61, p = 0.002). In contrast, in type 2 diabetic patients, plasma PCSK9 was not associated with LDL-C, apoB and LDL-apoB FCR. However, the lack of association between PCSK9 and LDL-apoB FCR seemed to be limited to the patients with "uncontrolled" diabetes (HbA1c > 7%) since a borderline significant negative correlation between PCSK9 and LDL FCR (r = -0.70, p = 0.08) was retrieved in patients with HbA1c
Référence
Atherosclerosis. 2011 Nov;219(1):342-8
